瑞加诺生SPECT心肌灌注显像对终末期肾病患者预后的预测价值:迄今最大队列
单中心回顾性研究纳入1227例终末期肾病患者,分析瑞加诺生SPECT心肌灌注显像异常与主要不良心脏事件的关系。平均随访2.5±1.8年期间共发生60例(5%)MACE事件。MPI异常(SSS≥4)与MACE风险升高独立相关(校正HR 1.95,95%CI 1.15-3.32,P=.013),心肌缺血(SDS≥2)呈升高趋势但未达统计学显著(校正HR 1.63,95%CI 0.96-2.77,P=.072)。
要点
- MPI异常(SSS≥4)与终末期肾病患者MACE风险升高独立相关,校正HR 1.95。
- 心肌缺血(SDS≥2)与MACE风险呈升高趋势但未达统计学显著,校正HR 1.63。
- MPI异常严重程度与缺血负荷与MACE风险呈阶梯式升高相关。
核心结论
- 在迄今最大队列中,异常MPI对终末期肾病患者MACE风险具有增量预后价值。
- 鉴于样本量,本研究较既往报告提供了该人群更改进的风险估计。
研究设计与样本
- 单中心、回顾性研究,连续纳入接受瑞加诺生SPECT心肌灌注显像的终末期肾病患者。
- 共纳入1227例受试者,平均年龄54±13岁,男性占47%。
- 定量测定MPI异常严重程度与缺血负荷;主要终点为主要不良心脏事件(MACE),定义为心源性死亡或心肌梗死的复合终点。
- 平均随访2.5±1.8年。
主要发现
- 随访期间共观察到60例(5%)MACE事件。
- MPI异常(SSS≥4)与MACE风险升高相关,独立于并增量于相关临床协变量;校正风险比1.95,95%置信区间1.15-3.32,Δχ2=5.97,P=.013。
- 心肌缺血(SDS≥2)与MACE风险呈升高趋势;校正风险比1.63,95%置信区间0.96-2.77,Δχ2=3.12,P=.072。
- MPI异常的存在与严重程度及缺血负荷与MACE风险呈阶梯式升高相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data on the prognostic utility of regadenoson SPECT myocardial perfusion imaging (MPI) in patients with end-stage renal disease (ESRD). METHODS AND RESULTS: In a single-center, retrospective study, we analyzed consecutive ESRD patients who underwent regadenoson SPECT-MPI. The severity of MPI abnormalities and ischemic burden were determined quantitatively. The primary endpoint was major adverse cardiac events (MACE), defined as the composite of cardiac death or myocardial infarction. Among 1,227 subjects (mean age 54 ± 13 years, 47% men), 60 (5%) MACE were observed during a mean follow-up of 2.5 ± 1.8 years. The presence and severity of MPI abnormalities and ischemic burden were associated with a stepwise increase in MACE risk. Abnormal MPI (SSS ≥ 4) was associated with increased MACE risk, independent and incremental to relevant clinical covariates; adjusted hazard ratio, 1.95; 95% confidence interval, 1.15-3.32; Δχ2 = 5.97; P = .013. Myocardial ischemia (SDS ≥ 2) was associated with a trend towards increased MACE risk; adjusted hazard ratio, 1.63; 95% confidence interval, 0.96-2.77; Δχ2 = 3.12; P = .072. CONCLUSION: In the largest cohort to date, we demonstrated the incremental prognostic value of abnormal MPI in predicting MACE risk in ESRD patients. Given its size, our study provides improved risk estimates in this population compared to previous reports.
引用
- Kolkailah AA, Iskander M, Iskander F, et al. The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date. J Nucl Cardiol. 2020. PMID: 32632913. doi:10.1007/s12350-020-02259-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。